The MASCC/ISOO Mucositis Guidelines 2019 Update: introduction to the first set of articles
A partir de revues systématiques de la littérature, ce dossier présente les recommandations concernant les différentes stratégies (biomodulation, médicaments anti-inflammatoires, compléments nutritionnels, etc.) pour prévenir et/ou traiter une mucite buccale ou gastro-intestinale induite par les traitements chez les patients atteints d'un cancer
Résumé en anglais
The Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) is a partnership between two professional organizations focusing on research and education concerning all aspects of supportive care for cancer patients. These organizations collaborate closely regarding oral complications secondary to cancer or cancer therapy, including the common complication mucositis, which can affect any part of the gastrointestinal tract, depending on the type of cancer and therapy.
While the primary goal is to cure cancer, patients expect to be able to tolerate the complications associated with cancer therapy without compromising immediate and long-term quality of life. Accordingly, health care providers need safe and efficient treatment modalities to manage the complications of cancer therapy.
To this end, a tremendous worldwide research effort has been made to study interventions for mucositis, creating a massive body of literature. It is clear that clinicians and patients would benefit from a systematic assessment of the evidence that identifies the best available agents. Therefore, the Mucositis Study Group (MSG) of MASCC/ISOO decided to create a guide for clinicians, aiming to improve patient care.
The MSG includes health care professionals from the numerous disciplines involved in the care of cancer patients. The collaboration between physicians, dentists, nurses, psychologists, physical therapists, speech therapists, and pharmacists, as well as basic science researchers, provides the MSG with a wide range of perspectives and allows an in-depth assessment of the scientific evidence.
The first set of clinical practice guidelines for the management of mucositis was published in 2004 [1] and updated in 2007 and 2014 [2, 3]. Due to the broad spectrum of interventions for the management of mucositis, the MSG of MASCC/ISOO divided the topic into 8 sections. During the current systematic review and guideline update, all sections used the same methods and communication between the sections ensured that there were no gaps in the coverage of the literature. (...)
